Astellas faces competition for its Prograf drug for the first time as Novartis began selling a copy, threatening sales of the Japanese company’s biggest revenue generator. Astellas shares fell the most in five months.
Sandoz, a Novartis unit, said today it introduced a generic version of the drug in the U.S., the world’s largest pharmaceutical market. Prograf is the world’s best-selling drug to stop transplanted organs from being rejected and accounts for about 20 percent of sales at Tokyo-based Astellas.
No comments:
Post a Comment